دورية أكاديمية
Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.
العنوان: | Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort. |
---|---|
المؤلفون: | Nassar A; Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA, nassar.aziza@mayo.edu., Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW |
المصدر: | Breast cancer research and treatment [Breast Cancer Res Treat] 2015 May; Vol. 151 (1), pp. 89-97. Date of Electronic Publication: 2015 Apr 12. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Dordrecht : Kluwer Academic Original Publication: The Hague ; Boston : M. Nijhoff, c1981- |
مواضيع طبية MeSH: | Breast Neoplasms/*genetics , Fibrocystic Breast Disease/*genetics , Ki-67 Antigen/*biosynthesis , Mammary Glands, Human/*metabolism, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/complications ; Breast Neoplasms/pathology ; Female ; Fibrocystic Breast Disease/complications ; Fibrocystic Breast Disease/pathology ; Gene Expression Regulation, Neoplastic ; Humans ; Ki-67 Antigen/genetics ; Mammary Glands, Human/pathology ; Middle Aged ; Risk Factors |
مستخلص: | Sclerosing adenosis (SA) increases risk for invasive breast cancer (BC) 2.1 times relative to that in the general population. Here, we sought to evaluate whether the proliferation marker Ki-67 stratifies risk among women with SA. A nested case-control sample of patients with SA was obtained from the Mayo Clinic Benign Breast Disease Cohort. Ki-67 expression was evaluated in SA lesions and in the adjacent normal terminal duct lobular units (TDLU) in women who did (cases, n = 133) or did not (controls, n = 239) develop BC. Ki-67 was scored by intensity and number of positively stained cells per one high-power field (magnification, ×40) (40× HPF) for both SA and normal TDLU. Associations of Ki-67 expression with case-control status were assessed using conditional logistic regression. Higher Ki-67 expression was significantly associated with case-control status in both SA (P = 0.03) and normal background TDLU (P = 0.006). For the SA lesion, >2 average positively stained cells/40× HPF showed an adjusted odds ratio (OR) of 1.9 (95 % CI, 1.1-3.4) compared to samples with an average of ≤2 positively stained cells. For background TDLU, lobules with >2 but ≤6 average positively stained cells showed an adjusted OR of 1.3-1.5, whereas those with an average of >6 positively stained cells had an OR of 2.4 (95 % CI, 1.1-5.3) compared to those with an average of <2 positively stained cells. Among women with SA, increased Ki-67 expression in either the SA lesion or the normal background TDLU carried an approximately twofold increased odds of subsequent BC as compared to lower Ki-67 expression. |
References: | Diagn Cytopathol. 2011 May;39(5):333-40. (PMID: 21488176) Asian Pac J Cancer Prev. 2011;12(11):3101-5. (PMID: 22393997) Breast Cancer Res Treat. 2014 Feb;144(1):205-12. (PMID: 24510013) Am J Pathol. 1999 Dec;155(6):1811-5. (PMID: 10595909) Cytopathology. 2000 Aug;11(4):243-54. (PMID: 10983724) Br J Cancer. 2001 Apr 20;84(8):1064-9. (PMID: 11308255) Int J Cancer. 1983 Jan 15;31(1):13-20. (PMID: 6339421) Cancer. 1989 Nov 15;64(10):1977-83. (PMID: 2804888) Ann Surg Oncol. 1995 Sep;2(5):416-23. (PMID: 7496836) N Engl J Med. 2005 Jul 21;353(3):229-37. (PMID: 16034008) J Natl Cancer Inst. 2006 Nov 15;98(22):1600-7. (PMID: 17105983) Singapore Med J. 2007 Oct;48(10):958-68. (PMID: 17909685) Breast Cancer Res Treat. 2010 Jun;121(2):431-7. (PMID: 19774459) |
معلومات مُعتمدة: | P30 CA015083 United States CA NCI NIH HHS; P50 CA116201 United States CA NCI NIH HHS; UL1 TR000135 United States TR NCATS NIH HHS; P50CA116201 United States CA NCI NIH HHS |
المشرفين على المادة: | 0 (Ki-67 Antigen) |
تواريخ الأحداث: | Date Created: 20150413 Date Completed: 20160125 Latest Revision: 20181113 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC4409576 |
DOI: | 10.1007/s10549-015-3370-y |
PMID: | 25863475 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1573-7217 |
---|---|
DOI: | 10.1007/s10549-015-3370-y |